Cocaine use and heterosexual exposure to human immunodeficiency virus [see comments] NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Cocaine use and heterosexual exposure to human immunodeficiency virus [see comments]

Epidemiology. 1994 Jul;5(4):398-403. Unique Identifier : AIDSLINE MED/95002338
Larrat EP; Zierler S; Mayer K; Department of Community Health, Brown University School of; Medicine, Providence, RI.

Abstract: We examined the relation between recent cocaine use and heterosexual exposure to human immunodeficiency virus (HIV). Five hundred nineteen heterosexually active participants in the New England Behavioral Health Study, an HIV testing and counseling program, provided information for this study. The outcome measure included behaviors that increased the risk for exposure to HIV via contact with infected genital secretions. Nearly one-third (31.8%) of participants reported use of cocaine during the year before study entry. These individuals were 1.3 times [90% confidence interval (CI) = 1.1-1.7] more likely to risk HIV exposure than people not using cocaine during this period, with evidence of a dose-dependent relation among HIV-positive cocaine users. HIV-positive crack users were at 1.9 times greater risk (90% CI = 1.2-2.9) for HIV risk-taking behavior than those who did not use crack. The effect of cocaine was present even among those individuals without other injection drug use.
Keywords: Adult *Cocaine Cross-Sectional Studies Female Human *HIV Seropositivity/EPIDEMIOLOGY Male *Risk-Taking Sex Behavior Support, U.S. Gov't, P.H.S. JOURNAL ARTICLEKWDadultKWDcocainecross-sectionalstudiesfemalehumanKWDhivseropositivity/epidemiologymaleKWDrisk-takingsexbehaviorsupport,uKWDsKWDgov't,pKWDhKWDsKWDjournalarticle
Comment in: Epidemiology 1994 Jul;5(4):389-90
950130
M9510804

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .